Relatlimab plus nivolumab beneficial for previously untreated metastatic or unresectable melanoma

Saved in:
Bibliographic Details
Published inCancer Vol. 128; no. 10; p. 1887
Main Author O’Rourke, Kate
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 15.05.2022
Subjects
Antibodies, Monoclonal - therapeutic use
Humans
Immune Checkpoint Inhibitors
Melanoma
Melanoma - drug therapy
Melanoma - secondary
Metastases
Nivolumab - therapeutic use
Oncology
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
ObjectType-News-1
content type line 66
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.34227